These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 15540755)

  • 61. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
    Herschorn S; Kohan A; Aliotta P; McCammon K; Sriram R; Abrams S; Lam W; Everaert K
    J Urol; 2017 Jul; 198(1):167-175. PubMed ID: 28161352
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency.
    Han JY; Lee KS; Park WH; Park CH; Lee JG; Lee JZ; Kim DY; Na YG; Kwon DD; Choo MS
    PLoS One; 2014; 9(11):e112063. PubMed ID: 25401784
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.
    Taekema-Roelvink ME; Swart PJ; Kuipers ME; Krauwinkel WJ; Visser N; Smulders RA
    Clin Ther; 2005 Sep; 27(9):1403-10. PubMed ID: 16291413
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Redefining response in overactive bladder syndrome.
    Payne CK; Kelleher C
    BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
    Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P
    Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
    Dubeau CE; Kraus SR; Griebling TL; Newman DK; Wyman JF; Johnson TM; Ouslander JG; Sun F; Gong J; Bavendam T
    J Urol; 2014 Feb; 191(2):395-404. PubMed ID: 23973522
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.
    Abrams P; Malone-Lee J; Jacquetin B; Wyndaele JJ; Tammela T; Jonas U; Wein A
    Drugs Aging; 2001; 18(7):551-60. PubMed ID: 11482747
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia.
    Rackley R; Weiss JP; Rovner ES; Wang JT; Guan Z;
    Urology; 2006 Apr; 67(4):731-6; discussion 736. PubMed ID: 16618562
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Solifenacin succinate for the treatment of overactive bladder.
    Hoffstetter S; Leong FC
    Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):345-50. PubMed ID: 19331596
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
    Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
    Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
    Gittelman M; Weiss H; Seidman L
    J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
    van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
    Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
    Ohlstein EH; von Keitz A; Michel MC
    Eur Urol; 2012 Nov; 62(5):834-40. PubMed ID: 22695239
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.
    Swift S; Garely A; Dimpfl T; Payne C;
    Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of mirabegron, a β
    Takahashi S; Mishima Y; Kuroishi K; Ukai M
    Int J Urol; 2022 Jan; 29(1):7-15. PubMed ID: 34605079
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Solifenacin in the treatment of overactive bladder: results of a randomized double-blind, placebo-controlled study].
    Ibinaeva IS; Apolikhina IA; Makhmedzhanova FN; Muslimova SZ
    Urologiia; 2012; (5):24-8. PubMed ID: 23342612
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combined antimuscarinics for treatment of neurogenic overactive bladder.
    Nardulli R; Losavio E; Ranieri M; Fiore P; Megna G; Bellomo RG; Cristella G; Megna M
    Int J Immunopathol Pharmacol; 2012; 25(1 Suppl):35S-41S. PubMed ID: 22652160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.